<DOC>
	<DOCNO>NCT02656069</DOCNO>
	<brief_summary>This blind , randomize crossover study compare safety efficacy G-Pen™ ( glucagon injection ) Lilly Glucagon ( glucagon injection [ rDNA origin ] ) hypoglycemia rescue adult patient type 1 diabetes .</brief_summary>
	<brief_title>Safety Efficacy G-Pen™ Compared Lilly Glucagon Hypoglycemia Rescue Adult Type 1 Diabetics</brief_title>
	<detailed_description>This blind , randomize , Phase 3 comparative efficacy safety study adult type 1 diabetes . Patients complete screen procedure 60 day randomization determine eligibility enrollment treatment phase . The procedure evaluate efficacy G-Pen™ ( glucagon injection ) consist induce hypoglycemia intravenous administration regular insulin dilute normal saline . Each participant undergo two episode insulin-induced hypoglycemia , random order receive 1 mg G-Pen™ ( glucagon injection ) one episode 1 mg Lilly Glucagon episode . There wash period 7-28 day treatment visit . Blood glucose level monitor post-dosing , return plasma glucose concentration &gt; 70 mg/dL within 30 minute signify successful hypoglycemia rescue . As confirmation efficacy , subject complete questionnaire concerning change symptoms hypoglycemia follow treatment glucagon . Subjects return follow-up safety visit 3-14 day follow administration final dose glucagon .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>diagnose type 1 diabetes mellitus least 24 month usage daily insulin treatment random serum Cpeptide concentration &lt; 0.5 ng/mL pregnant nursing HbA1c &gt; 9.0 % renal insufficiency hepatic synthetic insufficiency aspartate alanine aminotransferase &gt; 3 time upper limit normal hematocrit less equal 30 % use &gt; 2.0 U/kg total insulin dose per day inadequate bilateral venous access arm congestive heart failure , New York Heart Association class II , III IV active malignancy within 5 year , except basal cell squamous cell skin cancer history breast cancer malignant melanoma major surgical operation within 30 day current seizure disorder . current bleeding disorder , treatment warfarin , platelet count 50,000 history pheochromocytoma disorder increase risk pheochromocytoma history insulinoma history glycogen storage disease . positive HIV , hepatitis C virus active hepatitis B virus infection whole blood donation 1 pint ( 500 mL ) within 8 week active substance alcohol abuse administration glucagon within 28 day participation study involve investigational drug device within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>